AGP Executive Report
Last update: 9 minutes agoMedical Innovation: Liechtenstein-based RefluxStop® maker reports Q2 momentum: sales up 60% year-on-year, a large Nature Scientific Reports study in 602 patients across 22 centers showing serious safety events and reoperations below 2%, plus new reimbursement support—now boosted by FDA PMA approval and a U.S. launch underway. Transplant Breakthrough: Hansa Biopharma says Australia’s first commercial living-donor kidney transplant used Idefirix (imlifidase) for highly sensitised patients, aiming to improve access when antibodies block compatibility. Royal Health Update: Norway’s King Harald (89) is hospitalized for hemolytic anemia complications after cortisone treatment led to fluid retention; he’s on sick leave and Crown Prince Haakon is regent. Public Health Tech & Safety: The EU Entry/Exit System (EES) is fully operational, replacing passport stamps with digital records and biometrics for non-EU short stays—relevant for travelers’ health access and border processing. Policy Watch: EU sanctions alignment expands to include Liechtenstein among countries backing Belarus restrictive measures.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
